Efficacy and safety of widely used treatments for macular oedema secondary to retinal vein occlusion: a systematic review by Julie Glanville et al.
Glanville et al. BMC Ophthalmology 2014, 14:7
http://www.biomedcentral.com/1471-2415/14/7RESEARCH ARTICLE Open AccessEfficacy and safety of widely used treatments for
macular oedema secondary to retinal vein
occlusion: a systematic review
Julie Glanville1*, Jacoby Patterson1, Rachael McCool1, Alberto Ferreira2, Kerry Gairy3 and Ian Pearce4Abstract
Background: Macular oedema secondary to retinal vein occlusion (RVO) can cause vision loss due to blockage of
the central retinal vein (CRVO) or a branch retinal vein (BRVO). This systematic review assessed the efficacies of
widely used treatments for macular oedema secondary to RVO and the feasibility of conducting indirect
comparisons between these therapies.
Methods: A systematic review was undertaken in November 2010, including a literature search for trials in medical
databases and relevant websites. Abstracts, conference presentations and unpublished studies were considered.
Studies were data-extracted and quality assessed by two independent researchers. Outcome measures included the
mean change in best corrected visual acuity (BCVA) from baseline in the study eye and/or number of patients
gaining at least 10 letters from baseline to 6 months or the nearest equivalent time point.
Results: Fourteen unique randomized controlled trials (RCTs) were identified. Ranibizumab 0.5 mg produced
greater improvements in BCVA at 6 months than sham in BRVO (mean difference 11.0 letters, 95% confidence
interval [CI] 7.83, 14.17) and CRVO (mean difference 14.10 letters, 95% CI 10.51, 17.69) in two double-blind
sham-controlled RCTs. Pooled data from two double-blind, sham-controlled RCTs showed that improvements in
BCVA were also significantly better for dexamethasone intravitreal (IVT) implant 0.7 mg compared with sham in patients
with BRVO or CRVO (mean difference 2.5 letters, 95% CI 0.7, 4.3); the difference was significant for BRVO alone, but
not CRVO alone. A significantly greater proportion of patients with BRVO gained ≥15 letters with laser therapy vs.
no treatment at 36 months in a large prospective RCT (odds ratio 3.16, 95% CI 1.25, 8.00), whereas no difference
was observed at 9 months in a smaller study. Three studies reported no benefit for laser therapy in CRVO. No indirect
comparisons with ranibizumab were feasible due to differences in study design and baseline characteristics.
Conclusions: Data from RCTs for ranibizumab and dexamethasone IVT demonstrate that both new agents constitute
significant improvements over the previously widely accepted standard of care (laser therapy) for the treatment of BRVO
and CRVO. However, head-to-head studies are needed to assess the relative efficacies of licensed therapies for RVO.
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retinal vein occlusionBackground
Retinal vein occlusion (RVO) is the second most com-
mon retinal vascular disease after diabetic retinopathy
and is an important cause of vision loss [1]. It is caused
by occlusion of veins at the back of the eye, which be-
come occluded by vascular clot, external compression or
vessel wall pathology [2]. Occlusion can occur either in* Correspondence: julie.glanville@york.ac.uk
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of the retinal veins (branch RVO, BRVO) that combine to
form the central vein; prognoses and outcomes vary de-
pending on which is occluded [3]. RVO can lead to fluid
leakage from capillaries draining into the obstructed vein,
caused in part by secretion of vascular endothelial growth
factor (VEGF) and interleukin-6, and resulting in thicken-
ing of the retina (oedema) [4]. Macular oedema is the
most common cause of vision loss from RVO [5]. If left
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Study (ETDRS) scale after 3 years, to an average level of
20/70, but full recovery of vision is generally not achieved
owing to persistent oedema and resulting structural
damage [6]. Prognosis is worse for patients with macu-
lar oedema secondary to CRVO, with visual acuity (VA)
declining over time if left untreated [7]. Both BRVO
and CRVO are associated with significant impairments
in vision-related quality of life (as measured by the Na-
tional Eye Institute visual function questionnaire, NEI-
VFQ) [8,9].
A number of therapies are currently available for the
treatment of RVO. Laser photocoagulation has been the
standard of care for treatment of BRVO in the UK [4]
based on the results of the BVOS study performed 30 years
ago [6]. However, poor vision persists despite photocoagu-
lation treatment in many patients, and its use is not rec-
ommended until 3 months after development of BRVO
[4]. Laser therapy was also investigated in patients with
CRVO, but was found to produce no improvement in VA
over no treatment [10]; hence, observation was the stand-
ard of care for CRVO in the UK for several decades [4].
Two new treatments – ranibizumab (Lucentis®, Novartis
AG, Basel, Switzerland) and dexamethasone intravitreal
(IVT) implant (Ozurdex®, Allergan, Irvine, CA, USA) –
have recently been approved for treatment of macular
oedema secondary to RVO in the UK, Europe and
USA [11-14]. Ranibizumab is a recombinant, human-
ized, monoclonal antibody fragment developed specif-
ically for IVT use, which binds with high affinity to
multiple VEGF isoforms and prevents binding of VEGF
to VEGF receptors 1 and 2 [15]; it is prescribed at a dose of
0.5 mg. Dexamethasone IVT is a sustained-biodegradable
implant containing the corticosteroid dexamethasone. Cor-
ticosteroids including dexamethasone are known to have
anti-inflammatory, anti-angiogenic properties and may in-
hibit the expression of VEGF and other proinflammatory
cytokines such as IL-6, ICAM-1 and MCP-1 [12,16-22];
it is prescribed at a dose of 0.7 mg. Two further therap-
ies are also used to treat RVO. Bevacizumab, a full-
length anti-VEGF antibody developed for treatment of
cancer, has not been developed or licensed for IVT use;
however, it is sometimes used to treat RVO. IVT triam-
cinolone (IVTA), a corticosteroid injection, with a simi-
lar mechanism of action to dexamethasone [16,23,24], is
used off-label for the treatment of RVO. Since this re-
view was undertaken, a third anti-VEGF treatment –
aflibercept (Eylea®, Bayer AG, Berlin, Germany) – has
been approved for treatment of macular oedema sec-
ondary to RVO [25].
It is important to consider the relative efficacy of the
available therapies for RVO with published data. This
systematic review was therefore performed to assess the
efficacy and safety of available treatments for RVO asreported in randomized controlled trials (RCTs), and to as-
sess the feasibility of conducting indirect comparisons be-
tween ranibizumab and other therapies available in the UK.
Methods
This systematic review was conducted using systematic
review methodology based on the Centre for Reviews
and Dissemination’s Guidance for Undertaking System-
atic Reviews [26]. The systematic review was conducted
according to a written protocol that defined the research
question, the inclusion criteria and methods for study
selection, criteria for assessment of study quality, the
data to be extracted and the analyses to be performed.
Searches and data extraction
A systematic literature search was performed on
18 November 2010 in core medical databases (Medline,
Embase, the Cochrane Library, Cumulative Index to Nurs-
ing and Allied Health Literature), and further searches
were performed in relevant websites including the Inter-
national Clinical Trials Registry Platform and the Associ-
ation of Research and Vision and Ophthalmology. The
main interventions included in the searches were ranibizu-
mab, bevacizumab, dexamethasone IVT and laser photo-
coagulation. Data for other interventions were included
only for comparisons with the main interventions. Details
of the search used for Medline are included in Additional
file 1 and study inclusion criteria are summarized in
Table 1. Abstracts, conference presentations and unpub-
lished studies were considered eligible for inclusion in
the review if they met the inclusion criteria; only RCTs
in English were included. Additional sources of data in-
cluded clinical study reports for ranibizumab [27-31],
the dexamethasone IVT manufacturer’s submission to
the National Institute for Health and Clinical Excellence
(NICE) for dexamethasone IVT and the Evidence Review
Group response [32,33] and results of the Global Evalu-
atioN of implantable dExamethasone in retinal Vein oc-
clusion with macular edemA (GENEVA) studies reported
within the ClinicalTrials.gov records [34,35].
The screening process was carried out by a single re-
searcher and checked by a second researcher; discrepan-
cies were resolved through discussion or a third researcher
(JG, FC, SB). Data extraction was carried out independ-
ently by two researchers and discrepancies were resolved
by discussion (JG, JP, FC, SB).
Outcome measures
When possible, data for BRVO and CRVO were extracted
separately. Mean change in best corrected VA (BCVA)
from baseline in the study eye and/or the number of pa-
tients gaining at least 10 letters from baseline to 6 months,
or nearest equivalent time point, were extracted for all
studies (Tables 2 and 3); data for the number of patients
Table 1 Inclusion criteria according to the population–
intervention–comparison–outcome (study design) model





Comparison Any of the interventions listed above and
any of the following:
1. Best supportive care
2. Grid pattern photocoagulation
3. Sham injections
4. Mixed treatment comparisons
Outcomes Data for BRVO and CRVO were extracted
separately where possible
Primary measures (at least one of the
following extracted for every study)
1. Mean change in BCVA from baseline
2. Number of patients gaining≥ 10 letters
from baseline to 6 months
Secondary measures extracted if available
1. Number of patients gaining≥ 15 letters
2. AEs
3. SAEs
4. Vision-related quality of life
Study design Randomized controlled trials of any publication date
AE, adverse event; BCVA, Best corrected visual acuity; BRVO, Branch retinal vein
occlusion; CRVO, Central retinal vein occlusion; IVT, Intravitreal; SAE, serious
adverse event.
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These outcome measures were chosen because a gain in
BCVA of at least 10 letters has been shown to be associ-
ated with a clinically relevant improvement in vision-
related quality of life [36-38], and a gain of at least
15 letters is recommended by the US Food and Drug
Administration as the primary endpoint measure for
treatments for visual impairment [39]. Other outcomes
extracted if available included adverse events (AEs), ser-
ious AEs (SAEs) and vision-related quality of life.Quality assessment, risk of bias and feasibility of
performing indirect comparisons
The quality and potential risk of bias of included studies
were assessed according to the minimum criteria specified
by the NICE guidelines [40]. Key points assessed included
method of randomization, blinding protocols and baseline
patient demographics (full details in Additional file 2).
Potential sources of bias were participants or care pro-
viders not blinded to treatment and unexpected imbal-
ances in rates of drop-out between groups. Evidence tosuggest that other outcome measures were also assessed
was recorded. The feasibility of performing indirect com-
parisons was assessed according to guidance from the
Australian Pharmaceutical Benefits Advisory Board,
because these are the only well established guidelines
currently available [41].
Statistical analysis
For dichotomous outcomes, results were presented as
Mantel–Haenszel odds ratios (ORs), with 95% confidence
intervals (CIs). For continuous outcomes, results were
presented as mean differences, with 95% CIs if data on
mean and standard deviation were identifiable, and pooled
data were analysed using weighted mean differences. In-
direct comparisons were to be performed dependent upon
the suitability of the data.
Results
In total, 5766 unique references were identified from the
searches. From these, 14 studies met the inclusion criteria.
The screening and selection process is shown in Figure 1.
Studies
Fourteen unique RCTs were included in the review.
Three studies compared ranibizumab with sham injec-
tion [42-44], three studies compared dexamethasone
IVT with sham injection [18,20], five studies compared
laser therapy with no treatment [6,10,45-47] and bevaci-
zumab was compared with sham injections in two stud-
ies [48,49] and with laser therapy in another study [50].
Efficacy data for mean change in BCVA and the percent-
age of patients gaining at least 10 or at least 15 letters
and key study details are provided in Tables 2 and 3. Key
comparative efficacy data are summarized in Table 4.
Efficacy
Ranibizumab
BRVO The efficacy of ranibizumab 0.5 mg and 0.3 mg
for treatment of BRVO has been investigated in a high-
quality, double-blind, sham-controlled RCT, the BRAnch
retinal Vein Occlusion: Evaluation of Efficacy and Safety
(BRAVO) study, involving 397 patients [43]. The pri-
mary endpoint for the study was the mean change in
BCVA at 6 months. Ranibizumab 0.5 mg produced
greater improvements in BCVA at 6 months than sham
and the difference was statistically and clinically signifi-
cant (mean difference, 11.0 letters, 95% CI 7.83, 14.17;
Table 4). The proportion of patients gaining at least
10 letters at 6 months was also significantly greater for
ranibizumab 0.5 mg than for sham (OR 5.48, 95% CI
3.18, 9.44). Improvements in BCVA over sham and in-
creases in the proportion of patients gaining at least
10 letters were both greater for ranibizumab 0.5 mg than
for the 0.3 mg dose (Table 4).
Table 2 Study design and key efficacy data for RCTs investigating treatments for BRVO (efficacy data are presented at















Russo et al [50] Moradian et al [49]
(data presented
at 6 weeks)
Study design Blinded RCT Blinded RCT RCT (blinding
not reported)
Blinded RCT Unblinded RCT Blinded RCT
Study qualitya 6/8 7/8 3/8 7/8 5/8 7/8
Treatment arms 1. RBZ 0.3 mg 1. Dex IVT 0.7 mg 1. Laser 1. Laser 1. Laser 1. IVB
2. RBZ 0.5 mg 2. Dex IVT 0.35 mg 2. No treatment 2. No treatment 2. IVB 2. Sham
3. Sham (laser) 3. Sham
Key inclusion/
exclusion criteria
Age ≥ 18 years Age ≥ 18 years VA < 0.6 VA≤ 20/40 logMAR ETDRS≤ 0.4 BCVA≤ 20/50
ETDRS BCVA:
20/50–20/400
BCVA < 20/50 CMT≥ 30 μm
Mean CST ≥ 250 μm
No. eyes (patients)
randomized per arm
1. 134 1. 291 1. 33 1. 43 1. 15 1. 42
2. 131 2. 260 2. 35 2. 35 2. 15 2. 39
3. 132 3. 279
Study duration 6 months 6 months 24 months 36 months 12 months 3 months
Efficacy
Mean change in BCVA,
mean (SD)
1. 16.6 (11.0)* 1. 7.4b* 1. 0.7 (0.2) NR 1. 0.68 (0.13) 1. 0.49 (0.32)*
2. 18.3 (13.2)* 2. NR 2. 0.7 (0.2) 2. 0.57 (0.16) 2. 0.75 (0.48)
3. 7.3 (13.0) 3. 4.9b logMAR
Number of patients gaining 1. 74 (55.2)* 1. 67 (23.0) NR NR 1. 7 (46.7) NR
≥ 15 letters (%) 2. 80 (61.1)* 2. NR 2. 11 (73.3)
3. 38 (28.8) 3. 56 (20.1)
Number of patients gaining 1. 99 (73.9)* 1. 120 (41.2)* NR 1. 28 (65.1)* NR NR
≥ 10 letters (%) 2. 103 (78.6)* 2. 55 (21.2) 2. 13 (37.1)
3. 53 (40.2) 3. 92 (33.0)
aStudy quality was judged on the following criteria: randomization, allocation, blinding, similarity of groups, loss to follow-up, imbalance between groups, reporting of
data from intention-to-treat group and whether the study was free of selective reporting. Detailed assessment of study quality is presented in Additional file 2.
bData taken from manufacturer’s submission to NICE [32] (standard deviations were not reported).
*Statistically significant compared with sham/no treatment.
BCVA, Best-corrected visual acuity; BRAVO, Ranibizumab for the Treatment of Macular Edema after BRAnch retinal Vein Occlusion: Evaluation of Efficacy and Safety;
BRVO, Branch retinal vein occlusion; BVOS, Branch Retinal Vein Occlusion Study; CMT, Central macular thickness; CST, Central subfield thickness; Dex IVT, Dexamethasone
intravitreal; ETDRS, Early Treatment Diabetic Retinopathy Study; GENEVA, Global EvaluatioN of implantable dExamethasone in retinal Vein occlusion with macular edemA;
IVB, Intravitreal bevacizumab; logMAR, Logarithm of minimum angle of resolution; RBZ, Ranibizumab; RCT, Randomized controlled trial; VA, Visual acuity; NR, Not reported;
SD, standard deviation.
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provement in BCVA could receive a single treatment
with laser therapy after month 3 of the treatment period,
as per standard of care. The proportion of patients who
received laser therapy during the first 6 months was
greater for the sham group than for the ranibizumab
0.5 mg group (55% vs. 20%).
CRVO Two studies have investigated the efficacy of rani-
bizumab compared with sham injections in patients with
CRVO [42,44]. A large, high-quality, double-blind, sham-
controlled RCT, the Ranibizumab for the Treatment of
Macular Edema after Central Retinal Vein OcclUsIonStudy: Evaluation of Efficacy and Safety (CRUISE),
assessed ranibizumab 0.5 mg and 0.3 mg in 392 patients
[42]. A second smaller, double-blind, sham-controlled
RCT, the randomized Study Comparing Ranibizumab to
Sham in Patients with Macular Edema Secondary to
Central Retinal vein OCClusion (ROCC), assessed ranibi-
zumab 0.5 mg versus sham injection in 29 patients [44].
The primary endpoint for CRUISE was the mean change
from baseline in BCVA at 6 months and the primary end-
points in ROCC were mean change from baseline in BCVA
and central macular thickness at 6 months. In both studies,
ranibizumab 0.5 mg produced greater improvements in
BCVA than did sham at 6 months; the difference between
Table 3 Study design and key efficacy data for RCTs investigating CRVO or CRVO and BRVO (efficacy data are presented at 6 months unless otherwise indicated)
Study design and
patient characteristics





Laatikainen et al [46]
(data presented at
12 months)





Kuppermann et al [20]
(BRVO and CRVO – data
presented at 3 months)







Study qualitya 6/8 4/8 7/8 5/8 5/8 5/8 Poster
only
7/8
Treatment arms 1. RBZ 0.3 mg 1. RBZ 0.5 mg 1. Dex IVT 0.7 mg 1. Laser 1. Laser 1. Laser 1. IVB 1. Dex IVT
2. RBZ 0.5 mg 2. Sham 2. Dex IVT 0.35 mg 2. No treatment 2. No treatment 2. No treatment 2. Sham 0.7 mg/




Age ≥ 18 years
ETDRS: 20/50–20/320
Mean CST: ≥ 250 μm
Age≥ 50 years
ETDRS: 6–73 letters
Age ≥ 18 years
BCVA < 20/50








1. 132 1. 15 1. 136 1. 68 1. 24 1. 15 NR 1. 35
2. 130 2. 14 2. 154 2. 72 2. 24 2. 19 2. 34
3. 130 3. 147
Study duration 6 months 6 months 6 months 36 months 12 months 28.5 months NR 6 months
Efficacy
Mean change in BCVA,
mean (SD)
1. 12.7 (15.9)* 1. 12 (20.0)* 1. 0.1b NR NR NR NR NR
2. 14.9 (13.2)* 2. 1 (17.0) 2. NR
3. 0.8 (16.2) 3. −1.8b
Number of patients
gaining≥ 15 letters (%)
1. 61 (46.2)* NR 1. 24 (17.6) NR NR NR NR NR
2. 62 (47.7)* 2. 26 (16.9)
3. 22 (16.9) 3. 18 (12.2)
Number of patients
gaining≥ 10 letters (%)
1. 82 (62.1)* NR 1. 36 (26.5) 1. 10 (14.7) 1. 2 (8.3) 1. 3 (20.0) NR 1. 31 (88.6)*
2. 92 (70.8)* 2. NR 2. 6 (8.3) 2. 2 (8.3) 2. 5 (26.3) 2. 15 (44.1)
3. 33 (25.4) 3. 35 (23.8)
aStudy quality was judged on the following criteria: randomization, allocation, blinding, similarity of groups, loss to follow-up, imbalance between groups, reporting of data from intention-to-treat group and whether the study
was free of selective reporting. Detailed assessment of study quality is presented in Additional file 2.
bData taken from manufacturer’s submission to NICE [32] (standard deviations were not reported).
*Statistically significant compared with sham/no treatment.
BCVA, Best-corrected visual acuity; BRVO, Branch retinal vein occlusion; CMT, Central macular thickness; CRUISE, Ranibizumab for the Treatment of Macular Edema after Central Retinal Vein OcclUsIon Study: Evaluation
of Efficacy and Safety; CVOS, Central Retinal Vein Occlusion Study; CRVO, Central retinal vein occlusion; CST, Central subfield thickness; Dex IVT, Dexamethasone intravitreal; ETDRS, Early Treatment Diabetic Retinopathy
Study; GENEVA, Global EvaluatioN of implantable dExamethasone in retinal Vein occlusion with macular edemA; IVB, intravitreal bevacizumab; RBZ, Ranibizumab; RCT, randomized controlled trial; ROCC, Study Comparing
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Figure 1 Screening and selection of relevant references.
RVO, retinal vein occlusion.
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http://www.biomedcentral.com/1471-2415/14/7ranibizumab and sham was clinically and statistically signifi-
cant for CRUISE (mean difference 14.1, 95% CI 10.51, 17.69)
but not for ROCC (mean difference 11.0, 95% CI –2.48,
24.48; Table 4). Analysis of pooled data from CRUISE
and ROCC yielded a significant gain in mean BCVA for
ranibizumab 0.5 mg over sham at 6 months (mean
difference 13.89, 95% CI 10.42, 17.37) [42,44].
The proportion of patients gaining at least 10 letters at
6 months was also significantly greater for ranibizumab
0.5 mg than for sham in CRUISE (OR 7.12, 95% CI 4.12,
12.29; Table 4). Improvements in BCVA over sham and
increases in the proportion of patients gaining at least
10 letters were both greater for ranibizumab 0.5 mg than
for the 0.3 mg dose (Table 4).
Dexamethasone IVT
The efficacy of dexamethasone IVT in patients with
BRVO or CRVO has been investigated in two large, high-
quality, prospective, multicentre, masked, parallel-groupRCTs in patients with BRVO or CRVO; the GENEVA
studies [18,32]. These studies compared dexamethasone
IVT 0.7 mg and 0.35 mg with sham injection. There was
no rescue therapy for patients not responding to treat-
ment. The trials collectively included 1267 patients and
the prospectively defined primary endpoint for pooled
data from the two studies was the time to reach a
15-letter improvement in BCVA from baseline. Data
were reported as pooled data from the two studies.
BRVO Significantly greater improvements in mean BCVA
were achieved at 6 months with dexamethasone IVT
0.7 mg than with sham injections (mean difference 2.5 let-
ters, 95% CI 0.6, 4.3, Table 4) [33]. The proportion of pa-
tients gaining at least 10 letters was also significantly
greater for patients receiving dexamethasone IVT 0.7 mg
than for sham at 6 months (OR 1.43, 95% CI 1.01, 2.01),
although there was no significant difference in the propor-
tion of patients gaining at least 15 letters at the same time
point (OR 1.19, 95% CI 0.80, 1.78) [18]. Improvements in
BCVA from baseline and in the proportion of patients
gaining at least 10 and at least 15 letters with dexa-
methasone IVT 0.7 mg peaked at 2 months and de-
clined thereafter.
CRVO Significantly greater improvements in mean BCVA
were achieved at 1, 2 and 3 months, but not at 6 months,
with dexamethasone IVT 0.7 mg than with sham injec-
tions. The mean difference peaked at 2 months (9.3 let-
ters, 95% CI 6.5, 12.1), decreased to 4.6 letters (95% CI
1.4, 7.8) at 3 months and was not statistically significant at
6 months [33]. Similarly, significant differences compared
with sham were demonstrated for the proportion of pa-
tients gaining at least 15 letters at 1 and 2 months, and at
least 10 letters at 1, 2 and 3 months, in patients receiving
dexamethasone IVT 0.7 mg, but differences were not sig-
nificant at 6 months for either endpoint (Table 4).
BRVO and CRVO One further study compared dexa-
methasone IVT 0.35 mg and 0.7 mg with observation in
patients with either BRVO or CRVO [20]. The study was
a prospective, multicentre RCT that recruited 315 patients
with macular oedema due to a variety of causes. Of these,
69 had RVO (not specified whether BRVO or CRVO) and
were treated with dexamethasone IVT 0.7 mg; the per-
centage of patients gaining at least 10 letters at 3 months
was significantly higher in patients receiving dexametha-
sone IVT (N = 35) than in those receiving sham (OR 9.82,
95% CI 2.84, 33.99).
Laser photocoagulation
BRVO The efficacy of laser photocoagulation compared
with no treatment/observation was assessed in patients
with BRVO in two studies; one performed by the Branch
Table 4 Efficacy comparator analysis for BRVO and CRVO (all data are presented at 6 months unless otherwise stated)




Laser vs. no treatme /
observation
IVB vs. sham IVB vs. laser
BRVO
Mean change in BCVA (measured by
ETDRS scale unless otherwise specified),
mean difference (95% CI)
9.30* (6.40, 12.20) [43] 11.0* (7.83, 14.17) [43] NR 2.5* (0.6, 4.3) [18] Battaglia Parodi et al months),
-0.01, (-0.08, +0.06)a [ ]




Number of patients gaining
≥ 15 letters, OR (95% CI)
3.05* (1.84, 5.07) [43] 3.88* (2.32, 6.49) [43] NR 1.19 (0.80, 1.78) [18] NR NR logMAR; 3.14
(0.68, 14.5) [50]
Number of patients gaining
≥ 10 letters, OR (95% CI)




Mean change in BCVA, mean
difference (95% CI)
11.9* (8.01, 15.79) [42] CRUISE, 14.10* (10.51, 17.69) [42]
ROCC, 11.0* (–2.48, 24.48) [44]
NR NR, NSc NR NR NR
Number of patients gaining
≥ 15 letters, OR (95% CI)
4.22* (2.38, 7.47) [42] CRUISE, 4.48* (2.52, 7.94) [42] 1.46 (0.76, 2.79) [18] 1.54 (0.79, 2.98) [18] NR NR NR
Number of patients gaining
≥ 10 letters, OR (95% CI)
4.82* (2.84, 8.18) [42] CRUISE, 7.12* (4.12, 12.29) [42] NR 1.15 (0.67, 1.97) [18] CVOS (12 months), 1.9 (0.65, 5.54)
[10] Laatikainen et al (1 months),
1.00 (0.13, 7.75) [46] M et al
(24 months), 0.70 (0.14 .56) [47]
NR NR
BRVO or CRVO
Number of patients gaining
≥ 10 letters, OR (95% CI)
NR NR NR 3 months, 9.82*
(2.84, 33.99) [20]
NR NR NR
aMeasured by Snellen chart score.
bMeasured in LogMAR, cThe difference was reported as being not statistically significant (pooled data for BRVO and CRVO show significant improvement for mea difference in BCVA: OR 2.5 [95% CI 0.7, 4.3]).
*Statistically significant difference between groups.
BCVA, Best-corrected visual acuity; BRVO, Branch retinal vein occlusion; BVOS, Branch retinal Vein Occlusion Study; CI, Confidence interval; CRUISE, Ranibizumab fo the Treatment of Macular Edema after Central Retinal
Vein OcclUsIon Study: Evaluation of Efficacy and Safety; CRVO, Central retinal vein occlusion; CVOS, Central retinal Vein Occlusion Study; Dex IVT, Dexamethasone travitreal; ETDRS, Early Treatment Diabetic Retinopathy
Study; IVB, intravitreal bevacizumab; logMAR, Logarithm of minimum angle of resolution; OR, Odds ratio; RBZ, Ranibizumab; ROCC, Study Comparing Ranibizumab o Sham in Patients with Macular Edema Secondary to
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http://www.biomedcentral.com/1471-2415/14/7Retinal Vein Occlusion Study (BVOS) group [6] and one
by Battaglia Parodi et al. [45]. Both studies were intended
to be masked, although 22% of the examinations at the
36-month time point in the BVOS had inadvertently be-
come unmasked.
The BVOS, performed between 1977 and 1984, was a
multicentre RCT involving 139 patients who received ei-
ther laser therapy or no treatment [6]; the study had an
average follow-up duration of 3.1 years. Data reported at
36 months showed that the proportion of patients gain-
ing at least 10 letters was significantly greater in patients
receiving laser therapy than in those receiving no treat-
ment (OR 3.16, 95% CI 1.25, 8.00). The cumulative pro-
portion of eyes that gained at least 10 letters since the
initial visit for two or more consecutive visits increased
throughout the study in both groups.
The second, more recent RCT for laser treatment in-
volved 77 patients [45]. Patients received a single treatment
of grid laser therapy at 3 months; at 9 months post-
treatment, there was no significant difference between
groups in mean change in BCVA from baseline (mean dif-
ference –0.01, 95% CI –0.08, 0.06).
CRVO The Central Retinal Vein Occlusion Study
(CVOS) group performed an RCT in 1995 involving
181 eyes [10]. Patients received either grid laser treat-
ment or no treatment at baseline; the primary endpoint
of the study was mean change in BCVA from baseline.
The designs of the other two smaller studies were simi-
lar [46,47]. Patients were followed up every 3 months
for assessment of BCVA and data are presented for
36 months for CVOS, 24 months for May et al. (1979)
and 12 months for Laatikainen et al. (1977).
All three studies reported the percentage of patients
gaining at least 10 letters; no statistically significant dif-
ferences between treatment groups were observed in any
of the studies at any time point assessed. In CVOS, there
were also no significant differences between treatment
groups in mean VA or the percentage of patients losing
two lines by 36 months, and VA changed little in either
group during the 36 months of follow-up.
Bevacizumab
BRVO Two studies assessed the effects of bevacizumab
in patients with BRVO; Moradian et al. compared beva-
cizumab with sham injections [49] and Russo et al. com-
pared bevacizumab with laser therapy [50]; the dose of
bevacizumab in both studies was 1.25 mg.
Moradian et al. performed a prospective RCTcomparing
bevacizumab and sham injections in 81 eyes with BRVO
[49]; patients received two injections, one at baseline and
one at 6 weeks. BCVA was measured using the Snellen
chart and converted into logarithm of minimum angle of
resolution (logMAR; lower score indicates better BCVA).At 6 weeks, patients treated with bevacizumab had a sig-
nificantly greater improvement in BCVA from baseline
than the sham group (mean difference [logMAR] –0.26,
95% CI –0.44, –0.08), although the difference was not sig-
nificant at 12 weeks.
Russo et al. conducted an unmasked RCT in 30 eyes
comparing bevacizumab versus laser therapy [50]. Pa-
tients received one treatment with laser therapy at base-
line and another at 3 months if no improvement was
observed. Patients treated with bevacizumab received
one injection at baseline, then injections every 3 months
until macular oedema resolved, as judged by optical co-
herence tomography. Mean BCVA was measured using
logMAR. Improvements in BCVA at 6 months were sta-
tistically, although not clinically, significant for bevacizu-
mab compared with laser therapy (mean difference
[logMAR] –0.11, 95% CI –0.01, –0.21). The difference
between groups in percentage of patients gaining at least
15 letters at the same time point was not statistically
significant.
CRVO Faghihi et al. (2008) performed a double-masked,
multicentre RCT in 101 patients with CRVO receiving
bevacizumab alone, bevacizumab plus IVTA or sham
treatment [48]. At 18 weeks, BCVA (measured using
logMAR) had improved in the bevacizumab-only group
(by 0.47) and had worsened in the sham group (by
0.009); the difference between groups was statistically
significant (P < 0.001). Error values were not reported
for this study; hence, the mean difference and 95% CIs
could not be calculated.
Safety
Only three of the papers identified in this review reported
detailed safety data; these provided results for ranibizumab
0.5 mg and 0.3 mg compared with sham injections (from
BRAVO and CRUISE) [42,43] and dexamethasone IVT
0.7 mg and 0.35 mg compared with sham injections (the
GENEVA studies) at 6 months (Table 5) [18,32]. No de-
tailed safety data were reported in the laser therapy or
bevacizumab studies.
The most notable difference between treatments was
the incidence of increased intraocular pressure (IOP),
which occurred in 25% of patients receiving dexametha-
sone IVT 0.7 mg. In addition, the proportion of patients
requiring IOP-lowering therapy increased from 6% at
baseline to 24% at 6 months in patients receiving dexa-
methasone IVT [18,32]. In contrast, the incidence of in-
creased IOP was 5.4% and 8.5% in patients receiving
ranibizumab 0.5 mg in BRAVO and CRUISE, respect-
ively [42,43]. The incidence of cataract was low following
treatment with ranibizumab 0.5 mg in both studies (< 4%)
and was slightly elevated in patients receiving dexa-
methasone IVT 0.7 mg compared with sham (7.3% vs.
Table 5 Incidence of ocular AEs following treatment with ranibizumab [42,43] and dex IVT [18,32] at 6 months
BRAVO [43]a CRUISE [42]a GENEVAb (BRVO and CRVO combined) [18,32]
Adverse event 0.5 mg Sham 0.5 mg Sham 0.7 mg Sham
N = 130 N = 131 N = 129 N = 129 N = 421 N = 423
Increased intraocular pressurec, N (%) 7 (5.4) 2 (1.5) 11 (8.5) 4 (3.1) 106 (25.2)d OR 28.54,
95% CI 11.48, 70.95
5 (1.2)d
Ocular hypertension, N (%) NR NR NR NR 17 (4.0) P = 0.002 3 (0.7)
Eye pain, N (%) 21 (16.2) 19 (14.5) 24 (18.6) 13 (10.1) 31 (7.4) 16 (3.8)
Cataract, N (%) 4 (3.1) 4 (3.1) 2 (1.6) 0 31 (7.3) 19 (4.5)
Endophthalmitis, N (%) 1 (0.8) 0 0 0 NR NR
Retinal detachment, N (%) 0 0 0 0 1 1
Iris neovascularization, N (%) 0 3 (2.3) 1 (0.8) 9 (7.0) 0 6 (1.4)
Retinal neovascularization, N (%) 0 5 (3.8) 2 (1.6) 3 (2.3) 3 (0.7) P = 0.032 11 (2.6)
Neovascular glaucoma, N (%) 0 0 0 2 (1.6) NR NR
Retinal tear, N (%) 0 0 0 0 NR NR
Vitreous haemorrhage, N (%) 2 (1.5) 6 (4.6) 7 (5.4) 9 (7.0) 10 (2.4) 12 (2.8)
Retinal haemorrhage, N (%) 19 (14.6) 16 (12.2) 10 (7.8) 13 (10.0) 12 (2.9) 10 (2.4)
aKey study eye AEs through month 6.
bOcular AEs in the study eye reported by > 2% of patients in any treatment group.
cDefined as ≥ 30 mmHg in BRAVO and CRUISE, and ≥ 25 mmHg in GENEVA.
dData from the manufacturer’s submission to the National Institute for Health and Clinical Excellence (NICE).
AE, adverse event; BRAVO, Ranibizumab for the Treatment of Macular Edema after BRAnch retinal Vein Occlusion: Evaluation of Efficacy and Safety; BRVO, Branch
retinal vein occlusion; CRUISE, Ranibizumab for the Treatment of Macular Edema after Central Retinal Vein OcclUsIon Study: Evaluation of Efficacy and Safety;
CRVO, Central retinal vein occlusion; dex IVT, Dexamethasone intravitreal; GENEVA, Global EvaluatioN of implantable dExamethasone in retinal Vein occlusion with
macular edemA; NR, Not reported.
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cases of endophthalmitis were observed with dexametha-
sone IVT 0.7 mg; one case was observed in BRAVO in a
patient receiving ranibizumab 0.5 mg. Retinal detachment
was reported in one patient receiving sham and one re-
ceiving dexamethasone IVT in the GENEVA studies; there
were no cases in BRAVO or CRUISE.
Feasibility of indirect comparisons
The main purpose of this review was to compare ranibizu-
mab with other available treatments for RVO in the UK.
The feasibility of performing indirect comparisons be-
tween ranibizumab and the other treatments was there-
fore assessed by considering the available studies and their
homogeneity according to detailed guidance from the
Australian Pharmaceutical Benefits Advisory Committee
[41] and additional guidance from NICE [51].
Figure 2a shows the potential indirect comparisons
that could be made for ranibizumab with the other treat-
ments for BRVO based on the identified literature. Com-
parisons need to be made via sham as this was the
comparator in the only study of ranibizumab in BRVO
(i.e. BRAVO) [43]. However, in this study, patients not
achieving sufficient improvement in BCVA could receive
laser therapy as in current clinical practice, which poten-
tially underestimates the benefit of ranibizumab in relation
to other treatments (Table 6). Other aspects of studydesign that add bias to indirect comparisons include: 1)
the Moradian and Battaglia Parodi studies involved fewer
than 100 patients compared with 397 patients in BRAVO,
which would affect the precision of the effect estimate that
would be captured in an indirect comparison; 2) the dur-
ation of follow-up was shorter in the Moradian study than
in BRAVO (3 months vs. the 6-month primary endpoint
in BRAVO) and was much longer in one of the laser stud-
ies (36 months), and 3) the two laser studies were not
blinded. Furthermore, the duration of macular oedema at
baseline was shorter in BRAVO than GENEVA (3.3–
3.7 months vs. 5.1–5.3 months across treatment groups,
respectively), which potentially underestimates the bene-
fits of dexamethasone IVT compared with ranibizumab. It
should be noted that duration of RVO in the GENEVA
studies was calculated at the baseline visit. Conversely, in
BRAVO and CRUISE, the duration of macular oedema
was calculated at screening, up to 28 days before the base-
line visit, which reduces the potential underestimation of
treatment benefits of dexamethasone IVT over ranibizu-
mab. In assessing feasibility of indirect comparisons, the
duration of macular oedema before treatment was still
considered important enough to hinder a robust analysis.
Overall, the magnitude and direction of these sources of
bias are difficult to determine. We therefore conclude
that robust indirect comparisons of active treatments
for BRVO are not feasible from the available published
literature.
Ranibizumab























Figure 2 Potential comparisons between ranibizumab and
other treatments for (a) BRVO and (b) CRVO. BRVO, branch
retinal vein occlusion; CRVO, central retinal vein occlusion; IVT,
intravitreal triamcinolone.
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could be made for ranibizumab with the other treatments
for CRVO. All comparisons needed to be made via sham,
the comparator in CRUISE. Although there is a second
sham-controlled study of ranibizumab, ROCC, this
smaller study did not report the proportion of patients
gaining at least 15 letters, the outcome measure common
to all the other studies, and hence cannot be considered
for this analysis. Comparison via sham was considered for
ranibizumab versus dexamethasone IVT based on data
from the GENEVA study. As observed for the comparison
for BRVO, the difference in duration of macular oedema
before study commencement between CRUISE and GEN-
EVA (2.9–3.6 months vs. 5.1–5.3 months across treatment
groups, respectively) may underestimate the benefits of
dexamethasone IVT compared with ranibizumab, although
the impact of this is reduced when the additional screening
period in CRUISE is taken into account (Table 6). Further-
more, baseline BCVA was lower in CRUISE than GENEVA
(47.4–49.2 letters vs. 53.9–54.8 letters across treatment
groups, respectively), adding bias towards ranibizumab.
Owing to uncertainties in the overall magnitude of bias,
we deemed indirect comparison between ranibizumab
and dexamethasone for the treatment of CRVO unfeas-
ible. One study that compared bevacizumab with sham
was identified [48]. However, standard errors were not re-
ported for this study, thus preventing performance of anindirect comparison between ranibizumab and bevacizu-
mab in patients with CRVO.Discussion
For several decades, laser therapy was the standard of care
for patients with BRVO in the UK [4]. This is largely based
on the results of the BVOS, conducted over 30 years ago,
which reported that significantly more patients receiving
laser therapy had gained at least 10 letters at 36 months
than patients receiving no treatment [6]. However, differ-
ences in the improvement in VA between the two treat-
ment groups became apparent only after 12 months, and
12% of patients treated with laser therapy experienced de-
creases in VA during the study, as judged by losing at least
two letters at two consecutive visits during the study.
More recent data from the Standard Care vs. Corticoster-
oid for Retinal Vein Occlusion (SCORE) study also show
limited benefit for laser therapy at 12 months (median
gain of six letters at 12 months) [23]. This is further sup-
ported by the fact that a more recent but smaller study re-
ported no benefit of laser therapy compared with no
treatment at 9 months [45]. In contrast, three studies
showed no benefit of laser therapy for the treatment of
CRVO, and laser therapy is not recommended for this in-
dication [10,46,47]. Ranibizumab and dexamethasone IVT
implant have recently been approved for treatment of vis-
ual impairment due to macular oedema secondary to both
BRVO and CRVO. It is therefore relevant to assess their
relative efficacy and safety, and to compare them with
other therapies.
Results from two large, high-quality, double-blind, sham-
controlled RCTs (BRAVO and CRUISE) reported ranibi-
zumab to be an effective treatment for both BRVO and
CRVO [42,43]. In both indications, ranibizumab 0.5 mg in-
duced statistically and clinically significant improvements
in BCVA and in the proportion of patients gaining at least
15 letters at 6 months. Furthermore, statistically significant
differences in the change in BCVA from baseline between
ranibizumab and sham were evident from day 7 onwards
in both studies. Supporting evidence for the effectiveness
of ranibizumab comes from a smaller, double-blind, sham-
controlled study in patients with CRVO (ROCC) [44],
which also reported statistically and clinically significant
differences between ranibizumab 0.5 mg and sham for im-
provement in BCVA at 6 months. It should be noted that
patients not achieving sufficient improvements at month 3
in BRAVO in either group could receive laser therapy, thus
possibly confounding the results from month 3 onwards.
However, the BVOS and SCORE studies showed that the
benefits of laser therapy are minimal within the first year
of treatment [6]; hence, the benefit of laser therapy in ei-
ther treatment group may not be evident at the 6-month
time point.
Table 6 Summary of similarities and differences between studies
Studies Similarities Differences
BRVO
Ranibizumab vs. dex IVT: BRAVO [43]
vs. GENEVA [18]
Design: double-blind Patients failing to achieve sufficient improvement in BCVA could
receive laser in BRAVODate of study
Duration of macular oedema before study commencement:
3.3–3.7 months vs. 5.1–5.3 months across treatment groups for





Ranibizumab vs. bevacizumab: BRAVO [43]
vs. Moradian [49]
Design: double-blind Patients failing to achieve sufficient improvement in BCVA could receive
laser therapy in BRAVO
Date of study
Size: 81 patients (Moradian) vs. 397 patients (BRAVO)
Patient age: 58 years (Moradian) vs. 66 years (BRAVO)
Duration of macular oedema at baseline: 6 weeks (Moradian)
vs. 3.5 months (BRAVO)
Duration of follow-up: 3 months (Moradian) vs. 6 months (BRAVO)
BCVA endpoint: change in logMAR reported for Moradian
Ranibizumab vs. laser: BRAVO [43]
vs. BVOS [6]
Patient demographics Patients failing to achieve sufficient improvement in BCVA could receive
laser therapy in BRAVO
Size
Design: double-blinded for BRAVO but single-blinded for BVOS (patients
were aware of their treatment)
Duration of follow-up: 6 months vs. 36 months
Ranibizumab vs. laser: BRAVO [43]
vs. Battaglia Parodi [45]
Patient demographics Patients failing to achieve sufficient improvement in BCVA could receive
laser in BRAVO
Size: 77 patients (Battaglia Parodi) vs. 397 patients (BRAVO)
Design: blinded for BRAVO but not reported for Battaglia Parodi
Duration of follow-up: 24 months (Battaglia Parodi) vs. 6 months (BRAVO)
Duration of BRVO: < 15 days for Battaglia Parodi vs. < 12 months for
BRAVO (inclusion criterion)
CRVO
Ranibizumab vs. dex IVT: CRUISE [42]
vs. GENEVA [18]
Design: double-blind Duration of macular oedema before study commencement:
2.9–3.6 months vs. 5.1–5.3 months across treatment groups for
CRUISE and GENEVA, respectivelyDate of study
Duration of follow-up:
6 months
Baseline BCVA: 47.4–49.2 letters vs. 53.9–54.8 letters across treatment groups
for CRUISE and GENEVA, respectively
Size
Patient demographics
Ranibizumab vs. laser: CRUISE [42]
vs. CVOS [10]
Size Design: blinded for CRUISE but single-blinded for CVOS (patients were
aware of their treatment)
Patient demographics
Duration of macular oedema at baseline: > 3 months for CVOS, < 12 months
for CRUISE (inclusion criteria)
Duration of follow-up: 36 months (CVOS) vs. 6 months (CRUISE)
Ranibizumab vs. laser: CRUISE [42]
vs. Laatikainen [46]
Patient demographics Size: 48 patients (Laatikainen) vs. 392 patients (CRUISE)
Design: blinded for CRUISE but not Laatikainen
Duration of follow-up: 12 months (Laatikainen) vs. 6 months (CRUISE)
Duration of macular oedema at baseline: < 3 months for Laatikainen
vs. < 12 months for CRUISE (inclusion criterion)
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Table 6 Summary of similarities and differences between studies (Continued)
Ranibizumab vs. laser: CRUISE [42]
vs. May [47]
Patient demographics Size: 34 patients (May) vs. 392 patients (CRUISE)
Design: blinded for CRUISE but not May
Duration of follow-up: 24 months (May) vs. 6 months (CRUISE)
CRVO duration at baseline: not specified for May vs. < 12 months for CRUISE
(inclusion criterion)
BCVA, Best corrected visual acuity; BRAVO, Ranibizumab for the Treatment of Macular Edema after BRAnch retinal Vein Occlusion: Evaluation of Efficacy and Safety;
BRVO, Branch retinal vein occlusion; BVOS, Branch retinal Vein Occlusion Study; CRUISE, Ranibizumab for the Treatment of Macular Edema after Central Retinal Vein
OcclUsIon Study: Evaluation of Efficacy and Safety; CRVO, Central retinal vein occlusion; CVOS, Central retinal Vein Occlusion Study; Dex IVT, Dexamethasone
intravitreal; GENEVA, Global EvaluatioN of implantable dExamethasone in retinal Vein occlusion with macular edemA; logMAR, Logarithm of minimum angle of
resolution; NR, Not reported.
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IVT 0.7 mg induced significant improvements in mean
BCVA at 6 months in patients with BRVO, although the
difference was not significant in patients with CRVO
[18]. In both indications, there was no significant differ-
ence between groups for the proportion of patients gaining
at least 15 letters at 6 months. However, significant differ-
ences for this endpoint were demonstrated at months 1, 2
and 3 in patients with BRVO, and at months 1 and 2 for
patients with CRVO. In both indications, improvements in
the proportion of patients gaining at least 15 letters peaked
at 2 months and declined thereafter, suggesting that the
duration of benefit is not sustained beyond 3 months fol-
lowing administration of a single implant of dexametha-
sone IVT 0.7 mg.
Results from open-label extension studies to BRAVO,
CRUISE and GENEVA (not included in this review as
they were not RCTs) have been reported and provide
further data on the efficacy and safety of ranibizumab up
to 24 months and dexamethasone IVT up to 12 months
[52-55]; in the extensions to BRAVO and CRUISE, all
patients received ranibizumab 0.5 mg on an as-needed
basis. These studies reported that improvements in
BCVA following 6 months of treatment with ranibizu-
mab were maintained up to 24 months in patients with
BRVO [52,55] and up to 12 months in patients with
CRVO, followed by a slight loss in BCVA between
months 12 and 24 [53,55]. In the extension to the GEN-
EVA studies, patients received an implant of dexametha-
sone IVT 0.7 mg at day 180 (i.e. a second implant for
those who received dexamethasone IVT at the start of
GENEVA and a first implant for those treated with sham
in GENEVA) [54]. The response to the second treatment
was similar to that observed with the first treatment and
the improvement in BCVA from baseline peaked at
2 months after administration of the implant and declined
thereafter.
In contrast to ranibizumab and dexamethasone IVT, evi-
dence for the efficacy of bevacizumab in BRVO and CRVO
is limited. This systematic review identified only two small
RCTs in BRVO [49,50] and a single RCT in CRVO, each
involving fewer than 100 patients. Statistically significantdifferences in improvement in BCVA at 1, 3, 6 and
12 months compared with laser therapy were reported in
one study in BRVO [50] and the second study reported sig-
nificantly greater improvements in BCVA at 6 weeks for
bevacizumab than for no treatment, although the difference
was not significant at 12 weeks [49]. A third study in CRVO
reported an improvement in BCVA for bevacizumab and
bevacizumab plus IVTA at 18 weeks compared with a de-
crease in BCVA for sham. Longer follow-up of larger
numbers of patients is required to assess meaningfully the
potential benefit of bevacizumab in this indication.
Results of the BRAVO, CRUISE and GENEVA studies
provide an assessment of the safety profile of ranibizu-
mab and dexamethasone IVT in patients with RVO.
Ranibizumab was generally well tolerated in BRAVO
and CRUISE [42,43], and the follow-up studies show
that this favourable safety profile was maintained in the
open-label extensions [52,53,55]. These findings are con-
sistent with the safety profile observed for ranibizumab
in other ocular conditions, including a low incidence of
endophthalmitis, few ocular SAEs, and low rates of ad-
verse systemic cardiovascular and cerebrovascular ef-
fects (for which there is an increased theoretical risk
when using anti-VEGF agents) [11,56-58]. Results from
the GENEVA study indicate that dexamethasone IVT
0.7 mg is associated with an increased risk of developing
elevated IOP at 6 months (occurred in 25.2% of eyes)
[18], which increased to 32.8% at 12 months in patients
who received two dexamethasone IVT 0.7 mg implants
[54]. The rate of cataract was increased compared with
controls at 6 months (7.3%), although the difference was
not significant; at 12 months, the rate of cataract in pa-
tients receiving two implants had increased to 29.8%.
This is in agreement with the known safety profile of
corticosteroids as evident in the SCORE study, which re-
ported a significantly higher incidence of elevated IOP
and cataract for IVTA than for laser therapy (in BRVO)
or observation (in CRVO) [23]. Given that retreatment
with dexamethasone IVT may well occur after 4 months
in clinical practice, rather than 6 months as in the GEN-
EVA studies [40], the incidence of elevated IOP and
cataract with dexamethasone IVT may well be higher in
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toring [56-58]. In contrast to ranibizumab and dexa-
methasone IVT, the safety profile of bevacizumab in
RVO has not been rigorously assessed. The incidence of
AEs was not reported for two of the bevacizumab stud-
ies [48,49], and the third study [50] reported minor local
adverse reactions related to treatment with bevacizumab
in 9 out of 15 patients during the first week following
the first injection. Bevacizumab is unlicensed for ocular
use and further detailed safety data and pharmacovigi-
lance in RVO are essential. Safety data were not rigor-
ously assessed in any of the studies of laser therapy.
However, laser therapy is widely used in various ocular
indications and is known to be associated with various
complications, including foveal burns, central visual field
defects, exacerbation of macular oedema and acute glau-
coma [59-61].
This review included published data for treatments
that were widely used and available at the time of the
study (November 2010). Since this systematic review
was undertaken, results from two large double-blind,
sham controlled RCTs (COPERNICUS and GALILEO)
have been reported and provide data on the efficacy and
safety of another anti-VEGF, aflibercept, in CRVO
[62-65]. These studies suggest that monthly injections of
aflibercept result in significant improvements in visual
acuity at month 6 compared with sham injections, and
that improvements were sustained for up to 12 months
with further injections administered pro re nata. Afliber-
cept was generally well tolerated, with a low incidence of
ocular SAEs [62-65]. Data on the efficacy and safety of
aflibercept would warrant inclusion in a future system-
atic review.Conclusions
In conclusion, data from high-quality RCTs for ranibi-
zumab and dexamethasone IVT have demonstrated that
both new agents have promising outcomes for the treat-
ment of BRVO and CRVO, and constitute significant
improvements over the previously widely accepted stan-
dards of care (laser therapy for BRVO and no treatment
for CRVO). Significant differences in study design and
patient baseline characteristics prevent indirect compar-
isons being made between these treatments. Ranibizumab
and dexamethasone IVT both produce rapid improve-
ments in BCVA. These improvements appear to be main-
tained with initial monthly therapy followed by treatment
as needed for ranibizumab, but decline 3 months after ad-
ministration of the dexamethasone IVT implant. Dexa-
methasone IVT is associated with a significantly greater
risk of increased IOP (which increased further with re-
peated treatment) and possibly an increased risk of cata-
ract than is sham.Head-to-head comparative studies are urgently needed
to assess the relative efficacies of available licensed therap-
ies for RVO. This is currently being assessed in three on-
going RCTs comparing ranibizumab with dexamethasone
IVT in patients with RVO; the COMO (NCT01427751)
and COMRADE B (NCT01396057) studies are being con-
ducted in patients with BRVO and the COMRADE C
study (NCT01396083) is being conducted in patients with
CRVO. Direct comparison of the licensed therapies with
laser monotherapy and the role of adjunctive laser therapy
are currently lacking. This issue is being addressed by the
RABAMES study (NCT00562406) comparing ranibizu-
mab, laser monotherapy and ranibizumab plus adjunctive
laser therapy in patients with BRVO; this study has been
completed and data are expected shortly. A further study
comparing similar treatment arms, the BRIGHTER study
(NCT01599650, EUDRACT 2011-002859-34), has begun
recruiting in Europe. Results from these studies should
help to clarify the roles of the licensed therapies in the
management of patients with RVO.
Additional files
Additional file 1: Database search strategy for MEDLINE and
MEDLINE In-Process.
Additional file 2: Assessment of study quality and risk of bias.
Abbreviations
AE: Adverse event; BCVA: Best corrected visual acuity; BRVO: Branch retinal
vein occlusion; CI: Confidence interval; CRVO: Central retinal vein occlusion;
IOP: Intraocular pressure; IVT: Intravitreal; IVTA: Intravitreal triamcinolone;
logMAR: Logarithm of minimum angle of resolution; OR: Odds ratio;
RCT: Randomized controlled trial; RVO: Retinal vein occlusion; SAE: Serious
adverse event; VA: Visual acuity; VEGF: Vascular endothelial growth factor.
Competing interests
Alberto Ferreira and Kerry Gairy are both employees and stakeholders of the
Novartis Group. Julie Glanville, Jacoby Patterson and Rachael McCool received
funding from Novartis to carry out reviews and generate economic models. Ian
Pearce acts as a consultant and lecturer for Novartis.
Authors’ contributions
Study protocol was developed by JG, AF and KG. All authors participated in
the development and writing of the manuscript, and approved the final
article for publication. JG, JP and RM also performed screening, data
extraction and synthesis, and assessment of feasibility of indirect
comparisons.
Acknowledgements
The authors are grateful to Steven Duffy for performing the literature
searches, and to Sophie Beale and Fay Crawford for assisting in screening,
data extraction and synthesis. The authors would also like to thank Rowena
Hughes and Adam Giles from Oxford PharmaGenesis™ Ltd for editorial
support in collating comments from authors and finalization of the
manuscript for submission. This project was funded by Novartis, Basel,
Switzerland.
Author details
1York Health Economics Consortium, University of York, York, UK. 2Novartis,
Basel, Switzerland. 3Novartis, Frimley, UK. 4St Paul’s Eye Unit, Royal Liverpool
University Hospitals NHS Trust, Liverpool, UK.
Glanville et al. BMC Ophthalmology 2014, 14:7 Page 14 of 15
http://www.biomedcentral.com/1471-2415/14/7Received: 25 February 2013 Accepted: 15 January 2014
Published: 21 January 2014References
1. Parodi MB, Bandello F: Branch retinal vein occlusion: classification and
treatment. Ophthalmologica 2009, 223(5):298–305.
2. Hayreh SS, Zimmerman MB, Podhajsky P: Incidence of various types of
retinal vein occlusion and their recurrence and demographic
characteristics. Am J Ophthalmol 1994, 117(4):429–441.
3. Wong TY, Scott IU: Clinical practice. Retinal-vein occlusion. N Engl J Med
2010, 363(22):2135–2144.
4. Royal College of Ophthalmologists: Retinal vein occlusion (RVO): interim
guidelines for management of retinal vein occlusion (RVO). London:
RCOpth; 2010. Available from: http://www.rcophth.ac.uk/core/core_picker/
download.asp?id=337.
5. Yau JW, Lee P, Wong TY, Best J, Jenkins A: Retinal vein occlusion: an
approach to diagnosis, systemic risk factors and management. Intern
Med J 2008, 38(12):904–910.
6. BVOS: Argon laser photocoagulation for macular edema in branch vein
occlusion. The branch vein occlusion study group. Am J Ophthalmol 1984,
98(3):271–282.
7. McIntosh RL, Rogers SL, Lim L, Cheung N, Wang JJ, Mitchell P, Kowalski JW,
Nguyen HP, Wong TY: Natural history of central retinal vein occlusion: an
evidence-based systematic review. Ophthalmology 2010,
117(6):1113–1123. e1115.
8. Awdeh RM, Elsing SH, Deramo VA, Stinnett S, Lee PP, Fekrat S: Vision-related
quality of life in persons with unilateral branch retinal vein occlusion using
the 25-item national eye institute visual function questionnaire.
Br J Ophthalmol 2010, 94(3):319–323.
9. Deramo VA, Cox TA, Syed AB, Lee PP, Fekrat S: Vision-related quality of life
in people with central retinal vein occlusion using the 25-item national
eye institute visual function questionnaire. Arch Ophthalmol 2003,
121(9):1297–1302.
10. CVOS: Evaluation of grid pattern photocoagulation for macular edema in
central vein occlusion. The central vein occlusion study group.
Ophthalmology 1995, 102(10):1425–1433.
11. Varma R, Wu J, Chong K, Azen SP, Hays RD: Impact of severity and
bilaterality of visual impairment on health-related quality of life.
Ophthalmology 2006, 113(10):1846–1853.
12. Ozurdex summary of product characteristics last updated December
2011. Available at: http://www.medicines.org.uk/emc/medicine/23422/SPC/
ozurdex/. Accessed July 2012.
13. Lucentis prescribing information (US) last updated June 2010. Available
at: http://www.gene.com/gene/products/information/pdf/lucentis-
prescribing.pdf. Accessed July 2012.
14. Ozurdex prescribing information (US) last updated February 2012.
Available at: http://www.allergan.com/assets/pdf/ozurdex_pi.pdf. Accessed
July 2012.
15. Pieramici DJ, Rabena M, Castellarin AA, Nasir M, See R, Norton T, Sanchez A,
Risard S, Avery RL: Ranibizumab for the treatment of macular edema
associated with perfused central retinal vein occlusions. Ophthalmology
2008, 115(10):e47–54.
16. McAllister IL, Vijayasekaran S, Chen SD, Yu DY: Effect of triamcinolone
acetonide on vascular endothelial growth factor and occludin levels in
branch retinal vein occlusion. Am J Ophthalmol 2009, 147(5):838–846.
e831-832.
17. Leopold IH: Nonsteroidal and steroidal anti-inflammatory agents. In
Surgical Pharmacology of the Eye. Edited by Sears ML, Tarkkanen A. New
York: Raven Press; 1985:83–133.
18. Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J,
Loewenstein A, Yoon YH, Jacques ML, Jiao J, et al: Randomized,
sham-controlled trial of dexamethasone intravitreal implant in patients
with macular edema due to retinal vein occlusion. Ophthalmology 2010,
117(6):1134–1146. e1133.
19. Koss MJ, Pfister M, Rothweiler F, Michaelis M, Cinatl J, Schubert R, Koch FH:
Comparison of cytokine levels from undiluted vitreous of untreated
patients with retinal vein occlusion. Acta Ophthalmol 2012,
90(2):e98–e103.
20. Kuppermann BD, Blumenkranz MS, Haller JA, Williams GA, Weinberg DV,
Chou C, Whitcup SM: Randomized controlled study of an intravitreousdexamethasone drug delivery system in patients with persistent macular
edema. Arch Ophthalmol 2007, 125(3):309–317.
21. Pfister M, Rothweiler F, Michaelis M, Cinatl J Jr, Schubert R, Koch FH,
Koss MJ: Correlation of inflammatory and proangiogenic cytokines from
undiluted vitreous samples with spectral domain OCT scans, in
untreated branch retinal vein occlusion. Clin Ophthalmol 2013,
7:1061–1067.
22. Wang K, Wang Y, Gao L, Li X, Li M, Guo J: Dexamethasone inhibits
leukocyte accumulation and vascular permeability in retina of
streptozotocin-induced diabetic rats via reducing vascular endothelial
growth factor and intercellular adhesion molecule-1 expression.
Biol Pharm Bull 2008, 31(8):1541–1546.
23. Scott IU, Ip MS, VanVeldhuisen PC, Oden NL, Blodi BA, Fisher M, Chan CK,
Gonzalez VH, Singerman LJ, Tolentino M: A randomized trial comparing
the efficacy and safety of intravitreal triamcinolone with standard care
to treat vision loss associated with macular edema secondary to branch
retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal
Vein Occlusion (SCORE) study report 6. Arch Ophthalmol 2009,
127(9):1115–1128.
24. Zhang X, Bao S, Lai D, Rapkins RW, Gillies MC: Intravitreal triamcinolone
acetonide inhibits breakdown of the blood-retinal barrier through differential
regulation of VEGF-A and its receptors in early diabetic rat retinas.
Diabetes 2008, 57(4):1026–1033.
25. Eylea prescribing information (US) last updated September 2012. Available
at: http://www.regeneron.com/Eylea/eylea-fpi.pdf. Accessed July 2012.
26. Center for Reviews and Dissemination: Systemtic Reviews: CRD’s guidance for
undertaking reviews in health care. York: CRD, University of York; 2009.
27. Gray S, Rubio R: A phase III, multicenter, randomized, sham injection-controlled
study of the efficacy and safety of ranibizumab injection compared with sham
in subjects with macular edema secondary to branch retinal vein occlusion
[Clinical Study Report]. Genentech: South San Francisco, CA; 2009.
28. Gray S, Rubio R: A phase III, multicenter, randomized, sham injection-controlled
study of the efficacy and safety of ranibizumab injection compared with sham
in subjects with macular edema secondary to branch retinal vein occlusion
[Clinical Study Report Addendum]. Genentech: South San Francisco, CA; 2009.
29. Gray S, Rubio R: A phase III, multicenter, randomized, sham injection-controlled
study of the efficacy and safety of ranibizumab injection compared with sham
in subjects with macular edema secondary to central retinal vein occlusion
[Clinical Study Report]. Genentech: South San Francisco, CA; 2010.
30. Gray S, Rubio R: A phase III, multicenter, randomized, sham injection-controlled
study of the efficacy and safety of ranibizumab injection compared with sham
in subjects with macular edema secondary to central retinal vein occlusion
[Clinical Study Report Addendum]. Genentech: South San Francisco, CA; 2010.
31. Singer M, Gray S, Yee Murahashi W, Saroj N, Rundle A, Rubio R: Subgroup
analyses of visual acuity outcomes in the bravo study of intravitreal
ranibizumab in patients with macular edema following branch retinal
vein occlusion. ARVO Meeting Abstracts 2010, 51:3561. Available from:
http://abstracts.iovs.org//cgi/content/abstract/51/5/3561.
32. Shyangdan D, Cummins E, Lois N, Royle P, Waugh N: Dexamethasone
implants (Ozurdex) for macular oedema after retinal vein occlusion. Single
technology appraisal (STA). AbHTAG; 2010. Available from: http://www.nice.
org.uk/nicemedia/live/13037/52883/52883.pdf.
33. Allergan: Dexamethasone intravitreal implant (Ozurdex®) for the treatment of
macular oedema caused by retinal vein occlusion. Single technology appraisal
(STA). Allergan; 2010. Available from: http://www.nice.org.uk/nicemedia/live/
13037/52863/52863.pdf.
34. Allergan: A study of the safety and efficacy of a new treatment for macular
edema resulting from retinal vein occlusion. NCT00168298; 2009. Available
from: http://ClinicalTrials.gov/show/NCT00168298.
35. Allergan: A Study of the Safety and Efficacy of a New Treatment for Macular
Edema Resulting From Retinal Vein Occlusion. NCT00168324; 2009. Available
from: http://ClinicalTrials.gov/show/NCT00168324.
36. Chang TS, Bressler NM, Fine JT, Dolan CM, Ward J, Klesert TR: Improved
vision-related function after ranibizumab treatment of neovascular
age-related macular degeneration: results of a randomized clinical trial.
Arch Ophthalmol 2007, 125(11):1460–1469.
37. Mangione CM, Lee PP, Gutierrez PR, Spritzer K, Berry S, Hays RD:
Development of the 25-item national eye institute visual function
questionnaire. Arch Ophthalmol 2001, 119(7):1050–1058.
38. Margolis MK, Coyne K, Kennedy-Martin T, Baker T, Schein O, Revicki DA:
Vision-specific instruments for the assessment of health-related quality
Glanville et al. BMC Ophthalmology 2014, 14:7 Page 15 of 15
http://www.biomedcentral.com/1471-2415/14/7of life and visual functioning: a literature review. Pharmacoeconomics
2002, 20(12):791–812.
39. Csaky KG, Richman EA, Ferris FL 3rd: Report from the NEI/FDA ophthalmic
clinical trial design and endpoints symposium. Invest Ophthalmol Vis Sci
2008, 49(2):479–489.
40. NICE: Single technology appraisal (STA). Specification for manufacturer/sponsor
submission of evidence. London: NICE; 2009.
41. PBAC: Report of the Indirect Comparisons Working Group to the
Pharmaceutical Benefits Advisory Committee: assessing indirect comparisons.
PBAC; 2008. Available from: http://www.pbs.gov.au/industry/useful-
resources/PBAC_feedback_files/ICWG%20Report%20FINAL2.pdf.
42. Brown DM, Campochiaro PA, Singh RP, Li Z, Gray S, Saroj N, Rundle AC,
Rubio RG, Murahashi WY: Ranibizumab for macular edema following
central retinal vein occlusion: six-month primary end point results of a
phase III study. Ophthalmology 2010, 117(6):1124–1133. e1121.
43. Campochiaro PA, Heier JS, Feiner L, Gray S, Saroj N, Rundle AC, Murahashi
WY, Rubio RG: Ranibizumab for macular edema following branch retinal
vein occlusion: six-month primary end point results of a phase III study.
Ophthalmology 2010, 117(6):1102–1112. e1101.
44. Kinge B, Stordahl PB, Forsaa V, Fossen K, Haugstad M, Helgesen OH, Seland
J, Stene-Johansen I: Efficacy of ranibizumab in patients with macular
edema secondary to central retinal vein occlusion: results from the
sham-controlled ROCC study. Am J Ophthalmol 2010, 150(3):310–314.
45. Battaglia Parodi M, Saviano S, Bergamini L, Ravalico G: Grid laser treatment
of macular edema in macular branch retinal vein occlusion.
Doc Ophthalmol 1999, 97(3–4):427–431.
46. Laatikainen L, Kohner EM, Khoury D, Blach RK: Panretinal photocoagulation
in central retinal vein occlusion: a randomised controlled clinical study.
Br J Ophthalmol 1977, 61(12):741–753.
47. May DR, Klein ML, Peyman GA, Raichand M: Xenon arc panretinal
photocoagulation for central retinal vein occlusion: a randomised
prospective study. Br J Ophthalmol 1979, 63(11):725–734.
48. Faghihi H, Piri N, Esfahani M, Aalami Z, Lashay A, Piri N, Faghihi S: Intravitreal
bevacizumab vs. combination of bevacizumab and triamcinolone vs. sham
treatment in Central Retinal Vein Occlusion. American Academy of
Ophthalmology Meeting Archives; 2008:271. Available from: http://aao.
scientificposters.com/epsView.cfm?8o86zyfE5SMw0%2FURIHEaEPee1tSQz
RJzYw6PAGSTN9mNNuonO4x%2FYg%3D%3D.
49. Moradian S, Faghihi H, Sadeghi B, Piri N, Ahmadieh H, Soheilian M,
Dehghan MH, Azarmina M, Esfahani MR: Intravitreal bevacizumab vs. sham
treatment in acute branch retinal vein occlusion with macular edema:
results at 3 months (Report 1). Graefes Arch Clin Exp Ophthalmol 2011,
249(2):193–200.
50. Russo V, Barone A, Conte E, Prascina F, Stella A, Noci ND: Bevacizumab
compared with macular laser grid photocoagulation for cystoid macular
edema in branch retinal vein occlusion. Retina 2009, 29(4):511–515.
51. The National Institute for Health and Clinical Excellence: Guide to the
methods of technology appraisal last updated June 2008; 2012. Available at:
http://www.nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.
pdf.
52. Brown DM, Campochiaro PA, Bhisitkul RB, Ho AC, Gray S, Saroj N, Adamis AP,
Rubio RG, Murahashi WY: Sustained benefits from ranibizumab for macular
edema following branch retinal vein occlusion: 12-month outcomes of a
phase III study. Ophthalmology 2011, 118(8):1594–1602.
53. Campochiaro PA, Brown DM, Awh CC, Lee SY, Gray S, Saroj N, Murahashi WY,
Rubio RG: Sustained benefits from ranibizumab for macular edema
following central retinal vein occlusion: twelve-month outcomes of a phase
III study. Ophthalmology 2011, 118(10):2041–2049.
54. Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J,
Loewenstein A, Yoon YH, Jiao J, Li XY, et al: Dexamethasone intravitreal
implant in patients with macular edema related to branch or central
retinal vein occlusion twelve-month study results. Ophthalmology 2011,
118(12):2453–2460.
55. Heier JS, Campochiaro PA, Yau L, Li Z, Saroj N, Rubio RG, Lai P:
Ranibizumab for macular edema due to retinal vein occlusions
long-term follow-up in the HORIZON trial. Ophthalmology 2012,
119(4):802–809.
56. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP,
Schneider S: Ranibizumab versus verteporfin for neovascular age-related
macular degeneration. N Engl J Med 2006, 355(14):1432–1444.57. Elman MJ, Aiello LP, Beck RW, Bressler NM, Bressler SB, Edwards AR, Ferris FL III,
Friedman SM, Glassman AR, Miller KM, et al: Randomized trial evaluating
ranibizumab plus prompt or deferred laser or triamcinolone plus prompt
laser for diabetic macular edema. Ophthalmology 2010,
117(6):1064–1077. e1035.
58. Regillo CD, Brown DM, Abraham P, Yue H, Ianchulev T, Schneider S, Shams N:
Randomized, double-masked, sham-controlled trial of ranibizumab for
neovascular age-related macular degeneration: PIER Study year 1.
Am J Ophthalmol 2008, 145(2):239–248.
59. Aiello LM: Perspectives on diabetic retinopathy. Am J Ophthalmol 2003,
136(1):122–135.
60. Lovestam-Adrian M, Agardh E: Photocoagulation of diabetic macular
oedema complications and visual outcome. Acta Ophthalmol Scand 2000,
78(6):667–671.
61. Striph GG, Hart WM Jr, Olk RJ: Modified grid laser photocoagulation for
diabetic macular edema. The effect on the central visual field.
Ophthalmology 1988, 95(12):1673–1679.
62. Boyer D, Heier J, Brown DM, Clark WL, Vitti R, Berliner AJ, Groetzbach G,
Zeitz O, Sandbrink R, Zhu X, et al: Vascular endothelial growth factor Trap-Eye
for macular edema secondary to central retinal vein occlusion: six-month
results of the phase 3 COPERNICUS study. Ophthalmology 2012,
119(5):1024–1032.
63. Brown DM, Heier JS, Clark WL, Boyer DS, Vitti R, Berliner AJ, Zeitz O,
Sandbrink R, Zhu X, Haller JA: Intravitreal aflibercept injection for macular
edema secondary to central retinal vein occlusion: 1-year results from
the phase 3 COPERNICUS study. Am J Ophthalmol 2013, 155(3):429–437.
e427.
64. Holz FG, Roider J, Ogura Y, Korobelnik JF, Simader C, Groetzbach G, Vitti R,
Berliner AJ, Hiemeyer F, Beckmann K, et al: VEGF Trap-Eye for macular
oedema secondary to central retinal vein occlusion: 6-month results of
the phase III GALILEO study. Br J Ophthalmol 2013, 97(3):278–284.
65. Korobelnik JF, Holz FG, Roider J, Ogura Y, Simader C, Schmidt-Erfurth U, Lorenz K,
Honda M, Vitti R, Berliner AJ, et al: Intravitreal aflibercept injection for macular
edema resulting from central retinal vein occlusion: one-year results of the
phase 3 GALILEO study. Ophthalmology 2013, 121(1):202–208.
doi:10.1186/1471-2415-14-7
Cite this article as: Glanville et al.: Efficacy and safety of widely used
treatments for macular oedema secondary to retinal vein occlusion:
a systematic review. BMC Ophthalmology 2014 14:7.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
